Tables
Components of Per Member Per Year Cost Trend 1997-2002
Utilization of Common Drugs for the Top 25 Therapy Classes 2001-2002
Price Changes Due to Inflation for the Top 25 Therapy Classes 2001-2002
Price Changes for the Top 50 Common Brand Drugs 2001-2002
Price Changes Due to Therapeutic Mix for the Top 25 Therapy
Brand/Generic Mix for the Top 25 Therapy Classes 2001-2002
Changes in Units Per Prescription for the Top 25 Therapy
Percent of 2002 Ingredient Cost and Cost Per Prescription for the
Table 10:
Top 10 Therapy Classes Contributing to 2002 Trend
Table 11:
2001-2002 Summary and 2003-2007 Forecast for Major Therapy Classes
Table 12: Table A1:
Cost Per Prescription and PMPY Cost for Major Therapy
Table B1:
Total Medicaid Prescription Cost 1996-2001
Table B2:
PMPM Medicaid Prescription Drug Use 1996-2001
Table B3: Figures Figure 1:
National Health Expenditures for Selected Healthcare Accounts
Figure 2:
2002 Generic Conversion Rates for Glucophage® to Metformin and Market
Figure 3:
2002 Generic Conversion Rates for Zestril®/Prinivil® to Lisinopril andPrinzide®/Zestoretic to Lisinopril/HCTZ and Market Share for
Zestril®/Prinivil®, Prinzide®/Zestoretic, Lisinopril and Lisinopril/HCTZ
Figure 4:
U.S. Sales for Brand Products With Patent Expirations Between2003 and 2007
Figure 5:
Generic Fill Rate Fourth Quarter 1994 to Fourth Quarter 2007 (Estimated)
Figure 6:
Percent Change in Ingredient Cost Per Prescription Due to Inflation,
Therapeutic Mix, Brand/Generic Mix and Units 2001-2002
Figure 7:
Impact of New Drugs Introduced Since 1992 on 2002 Utilization and
Figure 8:
Percent of Ingredient Cost Accounted for by New Drugs Introduced Since 1992
Figure 9:
Percent Changes in Ingredient Cost 1996-1997 to 2006-2007
Figure 10: Figure 11:
Continuum of Approaches to Maximizing Generic Opportunities
E x p r e s s S c r i p t s , I n c . Figure A1:
Therapy Class Drug Market Share Trend — Gastrointestinals
Figure A2:
Therapy Class Drug Market Share Trend — Antidepressants
Figure A3:
Therapy Class Drug Market Share Trend — Antianxiety Agents
Figure A4:
Therapy Class Drug Market Share Trend — Antipsychotics
Figure A5:
Therapy Class Drug Market Share Trend — Anti-Rheum (NSAIDs)
Figure A6:
Therapy Class Drug Market Share Trend — Narcotic Analgesics
Figure A7:
Therapy Class Drug Market Share Trend — Migraine Products
Figure A8:
Therapy Class Drug Market Share Trend — Anticonvulsants
Figure A9:
Therapy Class Drug Market Share Trend — Antihypertensives
Figure A10:
Therapy Class Drug Market Share Trend — Calcium Blockers
Figure A11:
Therapy Class Drug Market Share Trend — Beta Blockers
Figure A12:
Therapy Class Drug Market Share Trend — Antihyperlipidemics
Figure A13:
Therapy Class Drug Market Share Trend — Antiasthmatics
Figure A14:
Therapy Class Drug Market Share Trend — Antihistamines
Figure A15:
Therapy Class Drug Market Share Trend — Decongestants/Nasal Steroids
Figure A16:
Therapy Class Drug Market Share Trend — Cough/Cold
Figure A17:
Therapy Class Drug Market Share Trend — Cephalosporins
Figure A18:
Therapy Class Drug Market Share Trend — Macrolides
Figure A19:
Therapy Class Drug Market Share Trend — Penicillins
Figure A20:
Therapy Class Drug Market Share Trend — Quinolones
Figure A21:
Therapy Class Drug Market Share Trend — Antivirals
Figure A22:
Therapy Class Drug Market Share Trend — Oral Contraceptives
Figure A23:
Therapy Class Drug Market Share Trend — Estrogens
Figure A24:
Therapy Class Drug Market Share Trend — Miscellaneous Endocrines
Figure A25:
Therapy Class Drug Market Share Trend — Dermatologicals
Figure A26:
Therapy Class Drug Market Share Trend — Oral Antidiabetics
Figure A27:
Therapy Class Drug Market Share Trend — Insulins
Figure A28:
Therapy Class Drug Market Share Trend — Anticancer
Figure B1: Figure B2:
Growth of Enrollment in Medicaid Managed Care Programs by Percent of Recipients 1991-2001
Figure B3:
Medicaid Spending as a Percent of Health Spending 1998
Figure B4:
Growth Rates in Each Type of Expenditure 1998-2000
Figure B5:
Total Medicaid Prescription Drug Costs vs. Number of Enrollees 1996-2001
Figure B6:
Medicaid PMPM Utilization vs. Cost Per Rx 1996-2001
p t s , I n c . 2 0 0 2 D r u g Tr e n d R e p o r t
Sigríður Jóhannsdóttir, sigrjoh@landspitali.isÞVAGLEGGIR: FRÁGANGUR, FESTIBÚNAÐUR OG UMHIRÐASjúklingar þurfa stundum að hafa þvaglegg en mörg vandamál geta komið upp tengt honum. Hér er farið yfir hvað þarf að huga að og sérstaklega hvernig á að Algengt er að setja þurfi þvaglegg hjá einstaklingum til skemmri eða lengri tíma. Í starfi mínu á þvagfæragöngude
Dept. of Computer Science, Faculty of Sciences, Vrije UniversiteitAmsterdam; de Boelelaan 1081a, 1081 HV Amsterdam, The NetherlandsAgents, and in particular mobile agents, offer a means for application developers tobuild distributed applications. Given homogeneity of agent platform and code base, agentmigration is possible. However, many agent platforms exist, differing substantially in thesupp